Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection

AIDS

Volumn 13, Issue 4, 1999, Pages 447-454

  Polo, Simona ^a   Veglia, Fabrizio ^a   Malnati, Mauro S ^a   Gobbi, Cecilia ^a   Farci, Patrizia ^b   Raiteri, Riccardo ^c   Sinicco, Alessandro ^c   Lusso, Paolo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

AIDS; Chemokines; Disease progression; Prognostic factors; RANTES

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN 1; RANTES;

ADULT; ARTICLE; BLOOD; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; RETROSPECTIVE STUDY;

ADULT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; RANTES; RETROSPECTIVE STUDIES;

EID: 0033545446     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199903110-00002     Document Type: Article

References (37)

1. Munoz A, Wang MC, Bass S, et al.: Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group. Am J Epidemiol 1989, 130:530-539.
2. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr: The multicenter AIDS cohort study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987, 126:310-317.
3. Munoz A, Kirby AJ, He YD, et al.: Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:496-505.
4. Levy JA, Mackewicz CE, Barker E: Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today 1996, 17:217-224.
5. Mackewicz CE, Ortega HW, Levy JA: CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991, 87:1462-1466.
6. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1α, MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815.
7. Berger EA: HIV entry and tropism: the chemokine receptor connection. AIDS 1997, 11 (Suppl A) S3-S16.
8. Scarlatti G, Tresoldi E, Bjorndal A, et al.: In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997, 3:1259-1265.
9. Connor RI, Sheridan KE, Ceradini D, et al.: Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997, 185:621-628.
10. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors. A review for clinicians. JAMA 1997, 277:145-153.
11. Hogg RS, O'Shaughnessy MV, Gataric N, et al : Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997, 349:1294.
12. Munoz A, Schrager LK, Bacellar H, et al.: Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Am J Epidemiol 1993, 137:423-438.
13. Fahey JI, Taylor JM, Detels R, et al.: The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990, 322:166-172.
14. Simmonds P, Beatson D, Cuthbert RJ, et al.: Determinants of HIV disease progression: six-year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet 1991, 338:1159-1163.
15. Mellors JW, Rinaldo CR Jr, Gupta R, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
16. Saksela K, Stevens CE, Rubinstein P, Taylor PE, Baltimore D: HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 1995, 123:641-648.
17. Sinicco A, Fora R, Raiteri R, et al.: Is the clinical course of HIV-1 changing? A cohort study. BMJ 1997, 314:1232-1237.
18. Centers for Diseases Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36:3-15.
19. Klinger MHF, Wilhelm D, Bubel S, Sticherling M, Schroeder JM, Kuehnel W: Immunocytochemical localization of the chemokines RANTES and MIP-1α within human platelets and their release during storage. Int Arch Allergy Immunol 1995, 107:541-546.
20. Kameyoshi Y, Dorschner A, Mullet AI, Christophers E, Shroder J-M: Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992, 176:587-592.
21. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, De Paoli P: Serum levels of RANTES and MIP-1α in HIV-positive long-term survivors and progressor patients [letter]. AIDS 1996, 10:1431-1432.
22. Krowka JP, Gesner MI, Ascher MS, Sheppard HW: Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals. Clin Immunol Immunopathol 1997, 85:21-27.
23. Weiss L, Si-Mohamed A, Girao P, et al.: Plasma levels of monocyte chemotactic protein-1, but not those of macrophage inhibitory protein-1α and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 1997, 176:1621-1624.
24. McKenzie SW, Dallalio G, North M, Frame P, Means RT Jr: Serum chemokine levels in patients with non-progressing HIV infection. AIDS 1996, 10:29-33.
25. Aukrust P, Muller F, Froland SS: Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis 1998, 177:1091-1096.
26. Muller P, Engelstadter M, Werner A, et al.: Increased serum and mRNA levels of RANTES associated with elevated levels of activated CD8+CD38+ T cells in HIV-1 infected individuals. Intervirology 1997, 40:263-270.
27. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M: Change in circulating levels of the chemokines macrophage inflammatory proteins 1α and 1β, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS 1997, 11:485-491.
28. Kakkanaiah VN, Ojo-Amaize EA, Peter JB: Concentrations of circulating beta-chemokines do not correlate with viral load in human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol 1998, 5:499-502.
29. Landay AL, Mackewicz C, Levy JA: An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993, 69:106-116.
30. Malnati MS, Tambussi G, Clerici E, et al.: Increased plasma levels of the C-C chemokine RANTES in patients with primary HIV-1 infection. J Biol Regul Homeost Agents 1997, 11:40-42.
31. Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust P: Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J 1998, 12:79-89.
32. Paxton WA, Martin SR, Tse D, et al., Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat Med 1996, 2:412-417.
33. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR5. Nature 1996, 381:667-673.
34. Schall TJ, Bacon KB: Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994, 6:865-873.
35. Baggiolini M, Dewald B, Moser B: Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1994, 55:97-179.
36. Pulsatelli L, Meliconi R, Boiardi L, Macchioni P, Salvarani C, Facchini A: Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica. Clin Exp Rheumatol 1998, 16:263-268.
37. Macchioni P, Boiardi L, Meliconi R, et al.: Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A. J Rheumatol 1998, 25:320-325.